Obesity startup Verdiva, seeing opportunity in a crowded market, raises $400M Series A

Taking stock of the drug industry, from the lab to the medicine chest

January 9, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

STAT+ | Obesity startup Verdiva, seeing opportunity in a crowded market, raises $400M Series A The new company did not develop its own pipeline, but rather licensed its collection of compounds from the Chinese firm Sciwind Biosciences. By Andrew Joseph STAT+ | German research team's discoveries open new possibilities for patients with autoimmune diseases German researchers, led by Georg Schett, achieved lupus remissions using CAR-T therapy, offering new hope for other autoimmune disease treatments. By Andrew Joseph STAT+ | Investors call on UnitedHealth to disclose human and economic costs of policies that limit care Health insurers like UnitedHealth are under tremendous public scrutiny for tactics such as prior authorization and care denials. By Tara Bannow Pharma's big patent cliff, more obesity fundraising, and a failed ALS study STAT reporters discuss why a looming patent cliff could lead to more pharmaceutical deal-making and a new obesity startup. By Elaine Chen, Allison DeAngelis, and Adam Feuerstein STAT+ | The Massachusetts biotech industry rebounded in 2024. Can the momentum last? "2024 showed us that the industry is on its way back up," said Ben Bradford, head of external affairs at MassBio, the state's biotech trade group. By Larry Edelman — Boston Globe

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser